Trametinib

Drug Profile

Trametinib

Alternative Names: 1120212; GSK-1120212; GSK-1120212B; JTP-74057; Mekinist; TMT 212

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Japan Tobacco
  • Developer Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Registered Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Endometrial cancer; Multiple myeloma; Pancreatic cancer; Uveal melanoma
  • Phase I/II Colorectal cancer; Solid tumours
  • Phase I Lymphoma; Mesothelioma
  • No development reported Leukaemia
  • Discontinued Inflammation

Most Recent Events

  • 11 Sep 2017 Interim efficacy and adverse events data from the phase III COMBI AD trial in Malignant-melanoma presented at the 42nd Congress of European Society for Medical Oncology (ESMO-2017)
  • 11 Sep 2017 Updated efficacy data from a phase II trial in Non-small cell lung cancer presented at the 42nd Congress of European Society for Medical Oncology (ESMO-2017)
  • 25 Aug 2017 GlaxoSmithKline plans a phase I/II trial in combination with GSK 525762 for Solid tumours and Small-cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) (NCT03266159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top